Comanche secures $75M to test preeclampsia siRNA in PhII, adds Scott Gottlieb to board
Summary
Co\xadmanche Bio\xadphar\xadma, an siR\xadNA biotech cre\xadat\xaded by vet\xader\xadans of The Med\xadi\xadcines Com\xadpa\xadny, has reeled in a $75 mil\xadlion Se\xadries B to test its drug can\xaddi\xaddate for preeclamp\xadsia, a preg\xadnan\xadcy com\xadpli\xadca\xadtion that im\xadpacts mil\xadlions of women each year.The Con\xadcord, MA-based biotech al\xadso said for\xadmer FDA Com\xadmis\xadsion\xader Scott Got\xadtlieb has joined its board in con\xadjunc\xadtion with an\xadnounc\xading the over\xadsub\xadscribed round from New En\xadter\xadprise As\xadso\xadciates (NEA), At\xadlas Ven\xadture, GV, F-Prime Cap\xadi\xadtal, Lil\xadly Asia Ven\xadtures and Longview Health\xadcare Ven\xadtures. Got\xadtlieb, a part\xadner at NEA, will be joined on the board by At\xadlas part\xadner David Grayzel, the com\xadpa\xadny said Wednes\xadday.Unlock this article instantly by becoming a free subscriber. Youll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.